Precision BioSciences, Inc

(NASDAQ:DTIL)

$10.93

Created with Raphaël 2.1.267-100100
STRONG BUY

Latest On Precision BioSciences, Inc (DTIL):

About Precision BioSciences, Inc (DTIL):

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T read more... cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

See Advanced Chart

General

  • Name Precision BioSciences, Inc
  • Symbol DTIL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 223
  • Fiscal Year EndDecember
  • IPO Date2019-03-28
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.precisionbiosciences.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 27.13
  • Price/Book (Most Recent Quarter) 10.17
  • Enterprise Value Revenue 25.31
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$1.89
  • Next Year EPS Estimate -$2.00
  • Next Quarter EPS Estimate -$0.56
  • Operating Margin -493%
  • Return on Assets -32%
  • Return on Equity -97%
  • Revenue 21.96 million
  • Earnings Per Share -$3.12
  • Revenue Per Share $0.43
  • Gross Profit 22.24 million
  • Quarterly Earnings Growth 51.3%
View More

Highlights

  • Market Capitalization 599.55 million
  • EBITDA -66426000
  • PE Ratio 4.64
  • Analyst Target Price $18.25
  • Book Value Per Share $1.22
View More

Share Statistics

  • Shares Outstanding 56.24 million
  • Shares Float 43.22 million
  • % Held by Insiders 1185%
  • % Held by Institutions 50.24%
  • Shares Short 3.39 million
  • Shares Short Prior Month 3.36 million
  • Short Ratio 3.25
  • Short % of Float 7%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • 52 Week High $16.6
  • 52 Week Low $4.55
  • 50 Day Moving Average 12.34
  • 200 Day Moving Average 9.17
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Precision BioSciences, Inc (DTIL) Dividend Calendar:

EPS
EPS Estimate
-$0.11-$0.11-$0.2-$0.2-$0.3-$0.3-$0.4-$0.4-$0.49-$0.49-$0.58-$0.58-$0.68-$0.68EPSQ1/2019Q1/2019Q2/2019Q2/2019Q3/2019Q3/2019Q4/2019Q4/2019Q1/2020Q1/2020Q2/2020Q2/2020Q3/2020Q3/2020Q4/2020Q4/2020Date

Precision BioSciences, Inc (DTIL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Precision BioSciences, Inc (DTIL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Precision BioSciences, Inc (DTIL) Chart:

Precision BioSciences, Inc (DTIL) News:

Below you will find a list of latest news for Precision BioSciences, Inc (DTIL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Precision BioSciences, Inc (DTIL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Latest DTIL Trades:

Precision BioSciences, Inc (DTIL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Precision BioSciences, Inc (DTIL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Precision BioSciences, Inc (DTIL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1185%
Institutional Ownership: 5024%